Home » ABBOTT RECEIVES FDA CLEARANCE FOR I-STAT BNP TEST TO DIAGNOSE CONGESTIVE HEART FAILURE
ABBOTT RECEIVES FDA CLEARANCE FOR I-STAT BNP TEST TO DIAGNOSE CONGESTIVE HEART FAILURE
July 31, 2006
Abbott announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its i-STAT BNP cartridge, a new point of care diagnostic test used to quickly assess the level of BNP (brain naturietic peptide) in patients in emergency rooms, heart failure clinics and observation units, laboratories and other critical care settings. BNP is a protein secreted into the bloodstream by heart tissue during congestive heart failure (CHF), a disease in which the heart loses its ability to adequately pump blood throughout the body, and which results in a build-up of fluid pressure inside the heart.
Abbott (http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0339.htm)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct